Palvella submits first NDA module for QTORIN rapamycin, dosing begins in angiokeratoma trial

Palvella Therapeutics reported second quarter 2026 results on August 4, 2026, with a cluster of pipeline and regulatory updates.

The company completed an in-person pre-NDA meeting with FDA which addressed nonclinical, clinical pharmacology, clinical information, and the planned evidence package for the NDA.¹ Following that meeting, FDA granted Palvella's request for Rolling Review of the QTORIN rapamycin NDA for microcystic LMs, allowing the Agency to begin reviewing completed portions of the application before submission of the full NDA.¹ Palvella then submitted the first module of its rolling NDA to the FDA seeking approval of QTORIN rapamycin for the treatment of microcystic LMs,¹ and said the Company remains on track to complete the NDA submission in the second half of 2026.¹ Palvella said it is preparing for a planned standalone commercial launch in the first half of 2027, if approved.¹

In cutaneous venous malformations, Phase 3 trial initiation remains on track for the fourth quarter of 2026 following completion of the planned End-of-Phase 2 meeting.¹

For angiokeratomas, Palvella dosed the first patients in LOTU, a multicenter Phase 2 trial evaluating Fast Track-designated QTORIN rapamycin for clinically significant angiokeratomas, a rare, chronic and debilitating isolated lymphatic malformation affecting an estimated more than 50,000 diagnosed patients in the U.S. and for which there are no FDA-approved therapies.¹ Topline results from LOTU are expected in the second half of 2027.¹

For the second product candidate, Phase 2 trial initiation expected in the second half of 2026¹ for QTORIN pitavastatin in disseminated superficial actinic porokeratosis.

Palvella also said it plans to announce the fourth target clinical indication for QTORIN rapamycin in the second half of 2026,¹ and separately plans to announce the third product candidate from the QTORIN platform in a serious, rare disease with no FDA-approved therapies in the second half of 2026.¹

On finances, the company reported cash, cash equivalents, and short-term investments as of June 30, 2026 were $250.6 million.¹